Does the media prefer ASND or RVMD?

In the previous week, Revolution Medicines had 8 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 18 mentions for Revolution Medicines and 10 mentions for Ascendis Pharma A/S. Revolution Medicines' average media sentiment score of 0.71 beat Ascendis Pharma A/S's score of 0.18 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Revolution Medicines 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ASND or ALNY?

In the previous week, Ascendis Pharma A/S had 3 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 7 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 0.33 beat Ascendis Pharma A/S's score of 0.18 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Alnylam Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, ASND or BIIB?

Biogen has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascendis Pharma A/S $814.57M 17.39 -$258M $12.89 17.62 Biogen $10.03B 3.31 $1.29B $5.65 39.74

Does the media prefer ASND or BIIB?

In the previous week, Ascendis Pharma A/S had 3 more articles in the media than Biogen. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 7 mentions for Biogen. Biogen's average media sentiment score of 1.05 beat Ascendis Pharma A/S's score of 0.18 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Biogen 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ASND or ROIV?

In the previous week, Ascendis Pharma A/S had 4 more articles in the media than Roivant Sciences. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 6 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.18 beat Ascendis Pharma A/S's score of 0.18 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Roivant Sciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, INSM or ASND?

Ascendis Pharma A/S has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 39.87 -$1.28B -$4.11 N/A Ascendis Pharma A/S $814.57M 17.39 -$258M $12.89 17.62

Is INSM or ASND more profitable?

Ascendis Pharma A/S has a net margin of 70.99% compared to Insmed's net margin of -76.94%. Ascendis Pharma A/S's return on equity of 32.54% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -76.94% -123.94% -44.30% Ascendis Pharma A/S 70.99% 32.54% 7.71%

Does the media prefer INSM or ASND?

In the previous week, Insmed and Insmed both had 10 articles in the media. Insmed's average media sentiment score of 0.71 beat Ascendis Pharma A/S's score of 0.18 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Ascendis Pharma A/S (ASND) Competitors

$227.14 -0.69 (-0.30%)

As of 01:02 PM Eastern

Compare

ASND vs. RVMD, ALNY, BIIB, ROIV, and INSM

Should you buy Ascendis Pharma A/S stock or one of its competitors? Ascendis Pharma A/S's main competitors and comparable companies include Revolution Medicines (RVMD), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Roivant Sciences (ROIV), and Insmed (INSM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Ascendis Pharma A/S compare to Revolution Medicines?

Ascendis Pharma A/S (NASDAQ:ASND) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

Ascendis Pharma A/S has a net margin of 70.99% compared to Revolution Medicines' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Revolution Medicines	N/A	-88.20%	-57.85%

Ascendis Pharma A/S has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	17.39	-$258M	$12.89	17.62
Revolution Medicines	$11.58M	3,867.08	-$1.13B	-$8.82	N/A

94.3% of Revolution Medicines shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Ascendis Pharma A/S has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

In the previous week, Revolution Medicines had 8 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 18 mentions for Revolution Medicines and 10 mentions for Ascendis Pharma A/S. Revolution Medicines' average media sentiment score of 0.71 beat Ascendis Pharma A/S's score of 0.18 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Revolution Medicines	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S presently has a consensus target price of $310.75, suggesting a potential upside of 36.81%. Revolution Medicines has a consensus target price of $234.33, suggesting a potential upside of 12.16%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, research analysts plainly believe Ascendis Pharma A/S is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	3.00
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	20 Buy rating(s)	2 Strong Buy rating(s)	2.96

Summary

Ascendis Pharma A/S beats Revolution Medicines on 10 of the 17 factors compared between the two stocks.

How does Ascendis Pharma A/S compare to Alnylam Pharmaceuticals?

Ascendis Pharma A/S (NASDAQ:ASND) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

Ascendis Pharma A/S has a net margin of 70.99% compared to Alnylam Pharmaceuticals' net margin of 15.26%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Ascendis Pharma A/S presently has a consensus target price of $310.75, suggesting a potential upside of 36.81%. Alnylam Pharmaceuticals has a consensus target price of $366.90, suggesting a potential upside of 56.09%. Given Alnylam Pharmaceuticals' higher probable upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	3.00
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83

Ascendis Pharma A/S has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

Alnylam Pharmaceuticals has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	17.39	-$258M	$12.89	17.62
Alnylam Pharmaceuticals	$4.80B	6.55	$313.75M	$5.38	43.69

In the previous week, Ascendis Pharma A/S had 3 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 7 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 0.33 beat Ascendis Pharma A/S's score of 0.18 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alnylam Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Alnylam Pharmaceuticals beats Ascendis Pharma A/S on 9 of the 17 factors compared between the two stocks.

How does Ascendis Pharma A/S compare to Biogen?

Ascendis Pharma A/S (NASDAQ:ASND) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

In the previous week, Ascendis Pharma A/S had 3 more articles in the media than Biogen. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 7 mentions for Biogen. Biogen's average media sentiment score of 1.05 beat Ascendis Pharma A/S's score of 0.18 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biogen	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market. Comparatively, Biogen has a beta of 0.17, meaning that its share price is 83% less volatile than the broader market.

87.9% of Biogen shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Comparatively, 0.3% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Biogen has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	17.39	-$258M	$12.89	17.62
Biogen	$10.03B	3.31	$1.29B	$5.65	39.74

Ascendis Pharma A/S has a net margin of 70.99% compared to Biogen's net margin of 8.32%. Ascendis Pharma A/S's return on equity of 32.54% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Biogen	8.32%	11.18%	6.88%

Ascendis Pharma A/S currently has a consensus price target of $310.75, suggesting a potential upside of 36.81%. Biogen has a consensus price target of $230.14, suggesting a potential upside of 2.49%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	3.00
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56

Summary

Ascendis Pharma A/S beats Biogen on 11 of the 16 factors compared between the two stocks.

How does Ascendis Pharma A/S compare to Roivant Sciences?

Ascendis Pharma A/S (NASDAQ:ASND) and Roivant Sciences (NASDAQ:ROIV) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

64.8% of Roivant Sciences shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Comparatively, 8.8% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Ascendis Pharma A/S has a net margin of 70.99% compared to Roivant Sciences' net margin of -3,534.96%. Ascendis Pharma A/S's return on equity of 32.54% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

Ascendis Pharma A/S presently has a consensus target price of $310.75, indicating a potential upside of 36.81%. Roivant Sciences has a consensus target price of $45.64, indicating a potential upside of 26.48%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, equities analysts plainly believe Ascendis Pharma A/S is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	3.00
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Ascendis Pharma A/S has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

Ascendis Pharma A/S has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	17.39	-$258M	$12.89	17.62
Roivant Sciences	$8.26M	3,155.30	-$299.77M	-$0.53	N/A

In the previous week, Ascendis Pharma A/S had 4 more articles in the media than Roivant Sciences. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 6 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.18 beat Ascendis Pharma A/S's score of 0.18 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Roivant Sciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Ascendis Pharma A/S beats Roivant Sciences on 12 of the 16 factors compared between the two stocks.

How does Ascendis Pharma A/S compare to Insmed?

Insmed (NASDAQ:INSM) and Ascendis Pharma A/S (NASDAQ:ASND) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

In the previous week, Insmed and Insmed both had 10 articles in the media. Insmed's average media sentiment score of 0.71 beat Ascendis Pharma A/S's score of 0.18 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	2 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ascendis Pharma A/S has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	39.87	-$1.28B	-$4.11	N/A
Ascendis Pharma A/S	$814.57M	17.39	-$258M	$12.89	17.62

Insmed presently has a consensus target price of $200.57, indicating a potential upside of 81.17%. Ascendis Pharma A/S has a consensus target price of $310.75, indicating a potential upside of 36.81%. Given Insmed's higher possible upside, analysts clearly believe Insmed is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	3.00

Ascendis Pharma A/S has a net margin of 70.99% compared to Insmed's net margin of -76.94%. Ascendis Pharma A/S's return on equity of 32.54% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
Ascendis Pharma A/S	70.99%	32.54%	7.71%

Insmed has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

Summary

Ascendis Pharma A/S beats Insmed on 7 of the 13 factors compared between the two stocks.

Get Ascendis Pharma A/S News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASND vs. The Competition

Export

Metric	Ascendis Pharma A/S	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$14.19B	$3.89B	$7.13B	$13.01B
Dividend Yield	N/A	3.63%	2.52%	14.40%
P/E Ratio	17.64	13.65	273.37	25.78
Price / Sales	17.39	1,295.97	656.74	105.59
Price / Cash	N/A	120.99	79.75	52.18
Price / Book	-76.48	15.70	10.53	6.26
Net Income	-$258M	-$22.67M	$3.49B	$360.84M
7 Day Performance	-1.54%	-2.61%	-2.03%	-1.88%
1 Month Performance	-12.72%	-8.57%	-5.22%	-3.41%
1 Year Performance	11.28%	23.88%	10.28%	2.64%

Ascendis Pharma A/S Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASND Ascendis Pharma A/S	4.8137 of 5 stars	$227.14 -0.3%	$310.75 +36.8%	+14.6%	$14.19B	$814.57M	17.64	1,189
RVMD Revolution Medicines	2.9292 of 5 stars	$201.74 -1.6%	$234.33 +16.2%	+339.5%	$43.93B	$11.58M	N/A	883	Analyst Forecast Analyst Revision
ALNY Alnylam Pharmaceuticals	3.7381 of 5 stars	$255.36 -0.2%	$367.20 +43.8%	-45.9%	$34.25B	$3.71B	47.46	2,770	Analyst Forecast
BIIB Biogen	2.5823 of 5 stars	$228.69 +0.5%	$230.14 +0.6%	+61.3%	$33.63B	$9.89B	40.48	7,500
ROIV Roivant Sciences	2.9282 of 5 stars	$36.98 +3.3%	$45.64 +23.4%	+141.7%	$25.86B	$8.26M	N/A	721

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASND) was last updated on 10/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ascendis Pharma A/S (ASND) Competitors

ASND vs. RVMD, ALNY, BIIB, ROIV, and INSM

How does Ascendis Pharma A/S compare to Revolution Medicines?

Summary

How does Ascendis Pharma A/S compare to Alnylam Pharmaceuticals?

Summary

How does Ascendis Pharma A/S compare to Biogen?

Summary

How does Ascendis Pharma A/S compare to Roivant Sciences?

Summary

How does Ascendis Pharma A/S compare to Insmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASND vs. The Competition

Ascendis Pharma A/S Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ascendis Pharma A/S (ASND) Competitors

ASND vs. RVMD, ALNY, BIIB, ROIV, and INSM

How does Ascendis Pharma A/S compare to Revolution Medicines?

Is ASND or RVMD more profitable?

Which has stronger valuation & earnings, ASND or RVMD?

Do insiders & institutionals hold more shares of ASND or RVMD?

Which has more risk and volatility, ASND or RVMD?

Does the media prefer ASND or RVMD?

Do analysts prefer ASND or RVMD?

Summary

How does Ascendis Pharma A/S compare to Alnylam Pharmaceuticals?

Is ASND or ALNY more profitable?

Do institutionals & insiders hold more shares of ASND or ALNY?

Do analysts rate ASND or ALNY?

Which has more volatility and risk, ASND or ALNY?

Which has higher valuation & earnings, ASND or ALNY?

Does the media prefer ASND or ALNY?

Summary

How does Ascendis Pharma A/S compare to Biogen?

Does the media prefer ASND or BIIB?

Which has more risk & volatility, ASND or BIIB?

Do insiders & institutionals hold more shares of ASND or BIIB?

Which has preferable earnings and valuation, ASND or BIIB?

Is ASND or BIIB more profitable?

Do analysts recommend ASND or BIIB?

Summary

How does Ascendis Pharma A/S compare to Roivant Sciences?

Do institutionals and insiders believe in ASND or ROIV?

Is ASND or ROIV more profitable?

Do analysts prefer ASND or ROIV?

Which has more risk and volatility, ASND or ROIV?

Which has better valuation & earnings, ASND or ROIV?

Does the media prefer ASND or ROIV?

Summary

How does Ascendis Pharma A/S compare to Insmed?

Does the media prefer INSM or ASND?

Which has better valuation & earnings, INSM or ASND?

Do analysts rate INSM or ASND?

Is INSM or ASND more profitable?

Which has more volatility & risk, INSM or ASND?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASND vs. The Competition

Ascendis Pharma A/S Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools